Advertisement

Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis

Published:April 07, 2021DOI:https://doi.org/10.1016/j.oret.2021.03.016

      Purpose

      To report an anatomic change following subretinal injection of voretigene neparvovec-rzyl (VN) for RPE65-mediated Leber congenital amaurosis.

      Design

      Multicenter, retrospective chart review.

      Participants

      Patients who underwent subretinal VN injection at each of 4 participating institutions.

      Methods

      Patients were identified as having perifoveal chorioretinal atrophy if (1) the areas of atrophy were not directly related to the touch-down site of the subretinal cannula; and (2) the area of atrophy progressively enlarged over time. Demographic data, visual acuity, refractive error, fundus photographs, OCT, visual fields, and full-field stimulus threshold (FST) were analyzed.

      Main Outcome Measures

      Outcome measures included change in visual acuity, FST, visual fields, and location of atrophy relative to subretinal bleb position.

      Results

      A total of 18 eyes of 10 patients who underwent subretinal injection of VN were identified as having developed perifoveal chorioretinal atrophy. Eight of 10 patients (80%) developed bilateral atrophy. The mean age was 11.6 years (range, 5–20 years), and 6 patients (60%) were male. Baseline mean logarithm of the minimum angle of resolution visual acuity and FST were 0.82 (standard deviation [SD], 0.51) and −1.3 log cd.s/m2 (SD, 0.44), respectively. The mean spherical equivalent was −5.7 diopters (D) (range, −11.50 to +1.75 D). Atrophy was identifiable at an average of 4.7 months (SD, 4.3) after surgery and progressively enlarged in all cases up to a mean follow-up period of 11.3 months (range, 4–18 months). Atrophy developed within and outside the area of the subretinal bleb in 10 eyes (55.5%), exclusively within the area of the bleb in 7 eyes (38.9%), and exclusively outside the bleb in 1 eye (5.5%). There was no significant change in visual acuity (P = 0.45). There was a consistent improvement in FST with a mean improvement of −3.21 log cd.s/m2 (P < 0.0001). Additionally, all 13 eyes with reliable Goldmann visual fields demonstrated improvement, but 3 eyes (23.1%) demonstrated paracentral scotomas related to the atrophy.

      Conclusions

      A subset of patients undergoing subretinal VN injection developed progressive perifoveal chorioretinal atrophy after surgery. Further study is necessary to determine what ocular, surgical delivery, and vector-related factors predispose to this complication.

      Keywords

      Abbreviations and Acronyms:

      AAV2 (adeno-associated virus 2), D (diopters), FST (full-field stimulus threshold), LCA (Leber congenital amaurosis), RPE (retinal pigment epithelium), SD (standard deviation), VN (voretigene neparvovec-rzyl)
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology Retina
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Allikmets R.
        Leber congenital amaurosis: a genetic paradigm.
        Ophthalmic Genet. 2004; 25: 67-79
      1. RetNet: Summaries.
        • Cideciyan A.V.
        • Aleman T.S.
        • Boye S.L.
        • et al.
        Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
        Proc Natl Acad Sci U S A. 2008; 105: 15112-15117
        • Russell S.
        • Bennett J.
        • Wellman J.A.
        • et al.
        Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
        Lancet. 2017; 390: 849-860
        • Maguire A.M.
        • Russell S.
        • Wellman J.A.
        • et al.
        Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation–associated inherited retinal dystrophy: results of phase 1 and 3 trials.
        Ophthalmology. 2019; 126: 1273-1285
        • Xiong W.
        • Wu D.M.
        • Xue Y.
        • et al.
        AAV cis-regulatory sequences are correlated with ocular toxicity.
        Proc Natl Acad Sci U S A. 2019; 116: 5785-5794
        • Bainbridge J.W.B.
        • Mehat M.S.
        • Sundaram V.
        • et al.
        Long-term effect of gene therapy on Leber’s congenital amaurosis.
        N Engl J Med. 2015; 372: 1887-1897
        • Cehajic-Kapetanovic J.
        • Xue K.
        • de la Camara C.M.-F.
        • et al.
        Retinal gene therapy in X-linked retinitis pigmentosa caused by mutations in RPGR: results at 6 months in a first in human clinical trial.
        Nat Med. 2020; 26: 354-359
        • Scruggs B.A.
        • Jiao C.
        • Cranston C.M.
        • et al.
        Optimizing donor cellular dissociation and subretinal injection parameters for stem cell-based treatments.
        Stem Cells Transl Med. 2019; 8: 797-809
        • Scruggs B.A.
        • Junior H.M.V.
        • Pennesi M.E.
        • et al.
        The age of patients with retinal degenerative diseases affects the injection pressure required for subretinal gene therapy delivery.
        Invest Ophthalmol Vis Sci. 2020; 61 (4501–4501)